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Pain from the female reproductive tract (FRT) is a signiﬁcant clinical problem for which
there are few effective therapies. The complex neuroanatomy of pelvic organs not only
makes diagnosis of pelvic pain disorders difﬁcult but represents a challenge to development
of targeted therapies. A number of potential therapeutic targets have been identiﬁed on
sensory neurons supplying the FRT but our knowledge on the basic neurophysiology of
these neurons is limited compared with other viscera. Until this is addressed we can only
guess if the new experimental therapies proposed for somatic, gastrointestinal, or bladder
pain will translate to the FRT. Once suitable therapeutic targets become clear, the next
challenge is drug delivery. The FRT represents a promising system for topical drug delivery
that could be tailored to act locally or systemically depending on formulation. Development
of these therapies and their delivery systems will need to be done in concert with more
robust in vivo and in vitro models of FRT pain.
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INTRODUCTION
Pain syndromes represent one of the major challenges of neu-
rology. Pain has many deﬁnitions but essentially it is a concept
generated across the brain in response to internal or external
stimuli that the individual associates with real or perceived tissue
damage or imminent threat (Merskey and Bogduk, 1994). Pain is
difﬁcult enough to treat when it arises from a relatively straightfor-
ward injury to a deﬁned region like a small piece of skin or a single
joint. Pain from pelvic organs, particularly the reproductive tract,
is notoriously difﬁcult to treat. In this review we will examine
the complex and unique innervation of the female reproduc-
tive tract (FRT), current treatments and the potential for topical
therapies.
The prevalence of transient pelvic pain (usually dysmenorrhea)
has been placed as high as 70–80% of women surveyed while
chronic pelvic pain was reported at >20% (Hillen et al., 1999;
Pitts et al., 2008). Ten percent of outpatient gynecological visits
are for intractable pelvic pain (Ryder, 1996), and pelvic pain is
the primary reason for 12–18% of hysterectomies (Kramer and
Reiter, 1997). United kingdom estimates from 2000 placed direct
healthcare costs at £158 million (Stones et al., 2000) whereas 1996
data from the USA placed patients’ out of pocket expenses at $1.9
billion dollars and indirect costs due to time off work at over $500
million (Mathias et al., 1996). Importantly many women do not
seek treatment for their pain (Mathias et al., 1996).
Chronic pelvic pain is further divided into “speciﬁc disease-
associated pelvic pain” and “chronic pelvic pain syndrome”
where the underlying pathology remains obscure (International
Association for the Study of Pain, 2011). Pelvic pain may
arise from a number of structures, both somatic (e.g., stri-
ated pelvic ﬂoor muscles), and visceral (reproductive tract,
bladder, and lower bowel). Focusing on reproductive struc-
tures, clinical observations have identiﬁed numerous predictors
of chronic pelvic pain including endometriosis, pelvic inﬂam-
matory disease, childbirth, and urinogenital atrophy fol-
lowing menopause (Giamberardino, 2008; Lara et al., 2009;
Paterson et al., 2009).
THE COMPLEX NATURE OF PAIN FROM THE FRT
Sexual behavior and reproduction rely on the integration of
nervous and hormonal signals to a widely distributed col-
lection of structures. The external genitalia are essentially
somatic structures and the distribution of sensory axons and
their neurochemical coding are similar to cutaneous tissues
(Martin-Alguacil et al., 2008; Moszkowicz et al., 2011; Vilimas
et al., 2011). Sensory neurons innervating the hollow organs
show different patterns of neurochemical expression compared
with those that supply somatic structures (skin, muscle, and
joints; Cervero and Laird, 2004; Song et al., 2009) and marked
differences in central axons termination in the spinal cord
(Sugiura et al., 1989, 1993).
Pain arising from the vagina, cervix, and uterus is an example of
visceral nociception – or pain that comes from distension, injury,
or inﬂammation of hollow organs (Cervero and Laird, 1999).
Visceral pain is diffuse, poorly localized, often referred to other
body regions, and can be accompanied by disrupted motor and
autonomic reﬂexes (Janig and Morrison, 1986; McMahon, 1997;
Westlund, 2000).
EXTERNAL GENITALIA
The most widely reported pain syndromes associated with exter-
nal genitalia are the vulvodynias (Petersen et al., 2008; Fugl-Meyer
et al., 2012). These have a prevalence of around 10% in U.S studies
(Harlow and Stewart, 2003; Petersen et al., 2008). Most sensations
from the external genitalia are transmitted via axons in the puden-
dal nerve (Martin-Alguacil et al., 2008; Moszkowicz et al., 2011;
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FIGURE 1 | Innervation of pelvic organs. Sensory axons innervating the
vagina reach the spinal cord via pelvic nerves and terminate in sacral spinal
cord segments (S2–S4). Axons innervating the uterus travel in the
hypogastric nerves and terminate in the thoracolumbar spinal cord
segments (T10–L2). The region surrounding the cervix represents a
transitional zone and is innervated by ﬁbers that travel in both nerves.
Sensory axons from the clitoris and vulva follow the pudendal nerves to
sacral spinal cord. Note that sensory information from all pelvic organs may
converge onto the same spinal cord neural circuits. DRG (dorsal root
ganglia).
Vilimas et al., 2011; Figure 1). Limited data indicate that often
pain from these structures is similar to generalized somatic pain
as opposed to visceral pain (Bachmann et al., 2006; Goldstein and
Burrows, 2008).
SENSATIONS FROM THE VAGINA, CERVIX AND UTERUS ENTER THE
CNS AT MULTIPLE LEVELS
The walls of the FRT are innervated with sensory afferent termi-
nals that respond to both distension and inﬂammatory mediators
(Berkley et al., 1993b; Papka and Traurig, 1993). The FRT is
innervated via two main spinal nerve trunks; the hypogastric
and pelvic nerves that send sensory information to a num-
ber of spinal cord segments (Figure 1; Berkley et al., 1993a,b;
Wesselmann and Lai, 1997;Wesselmann, 2001; Jobling et al., 2003,
2010).
Electrical recordings from axons in rodents indicate that there
is a heterogeneous distribution of receptors. Most axons respond
to distension, whilst others respond to both distension and chem-
ical stimuli (e.g., bradykinin or serotonin; Berkley et al., 1993a,b).
Compared with the FRT, sensory axons supplying the gastroin-
testinal tract (GIT) and bladder have been better studied. Five
functional classes of sensory axons have been described in the
GIT (Page et al., 2002; Brierley et al., 2004; Song et al., 2009)
and four functional classes of bladder sensory axons have been
identiﬁed (Zagorodnyuk et al., 2007). There is an extensive inter-
action between vagina, cervix, uterus, and somatic structures
(Hotta et al., 1999) where there is considerable convergence of
these pathways in the spinal cord. The most widely and long-
recognized consequence of this convergence is referred pain
(Head, 1893).
CENTRAL SENSITIZATION “PELVIC PAIN WITHOUT PELVIC
ORGANS”
Asigniﬁcant barrier to treatment is the observation that pelvic pain
can exist in the absence of any obvious pathology. In fact pelvic
pain is often resistant to the removal of the allegedly offending
organs (Baskin andTanagho, 1992). This observation is thought to
be caused by the phenomenon of central sensitization. The mech-
anisms underlying central sensitization for somatic afferents have
been examined in detail (Millan, 1999; Jones and Sorkin, 2003;
Lu et al., 2009), however, central sensitization from FRT affer-
ents remain poorly understood. Inﬂammation of the rat uterus
increased receptive ﬁeld size, and decreased thresholds for cervix
afferents (Berkley et al., 1993a). Another study has shown that FRT
inﬂammation recruits large numbers of neurons in the dorsal horn
(Wesselmann et al., 2000).
PELVIC ORGAN CROSSTALK – LINKING VAGINA, CERVIX,
UTERUS BLADDER, AND BOWEL
Epidemiological data suggest strong comorbidity between inﬂam-
matory bowel disorders, interstitial cystitis, and pelvic pain
(Whorwell et al., 1986). Some of this comorbidity might be
explained by the sensory and motor pathways that link FRT, blad-
der, and lower bowel (Winnard et al., 2006; Klumpp and Rudick,
2008). Sensations from these organs share synaptic circuits in the
spinal cord (Wyndaele et al., 2013) and may even share individ-
ual sensory neurons (Figure 1; Christianson et al., 2007). These
functional and anatomical interactions have implications for the
effectiveness of local topical therapies designed to act on one organ
only.
OVARIAN HORMONES ALTER SENSORY INNERVATION AND
PAIN THRESHOLDS
Fluctuations in levels of ovarian hormones, particularly estro-
gen, are associated with changes in sensation, including pain,
in a variety of tissues (Martin, 2009). This effect of estrogen
on pain responses is no doubt due to the widespread expres-
sion of estrogen receptors which are located, not only in the FRT,
but also on primary sensory neurons, spinal cord neurons, and
higher brain centers (Papka et al., 2001; Papka and Mowa, 2003;
Vanderhorst et al., 2009; Takanami et al., 2010). Notably, estrogen
receptors are particularly concentrated in sacral spinal cord seg-
ments that are crucial to the control of pelvic organs (Vanderhorst
et al., 2009). The role of estrogen in modulation of the nervous
system is unclear (Balthazart and Ball, 2006). Estrogen can inﬂu-
ence several receptors and ion channels in peripheral, spinal and
supraspinal pathways. For example transient receptor potential
(TRP) channels on primary afferent neurons are inhibited by
activation of the beta subtype estrogen receptor (ERβ; Xu et al.,
2008).
OVARIAN HORMONE WITHDRAWAL ALTERS FRT AND CUTANEOUS
SENSITIVITY
In humansmenopause is associatedwith a drastic decrease in levels
of ovarian hormones (Martin, 2009). With this altered hormonal
status many women have increased pain from the FRT, especially
the vagina, and some somatic tissues (Fillingim and Edwards,
2001; Samsioe, 2007; Martin, 2009). This post-menopausal
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vaginal hyperalgesia, typically presents as pain during intercourse
(dyspareunia; Davis et al., 2005; Mac Bride et al., 2010). Vari-
ous explanations have been proposed including vaginal atrophy
(Forsberg, 1995). However the severity of pain is only loosely cor-
related with vaginal wall thickness (Kao et al., 2008), suggesting
other factors are critical in this condition. Many of the painful
urinogenital symptoms can be reversed by conventional systemic
estrogen replacement although an increasing alternative is the
use of local intravaginal estrogen replacement (Mac Bride et al.,
2010).
PERIPHERAL THERAPEUTIC TARGETS
Precise information about the nature of primary sensory affer-
ent endings in uterus, cervix, and vagina is scant compared with
somatic (Woolf and Ma, 2007) or other visceral targets (Black-
shaw et al., 2007). Anatomical data from animals (Papka et al.,
1985, 1995, 1999; Shew et al., 1991; Collins et al., 2002) and,
rarely, humans (Fried et al., 1990; Bokor et al., 2009; Malvasi et al.,
2010) suggest they express the same neurochemical markers and
receptors as nearby viscera, e.g., bladder and bowel.
OPIOIDS
Enkephalin immunoreactive axons in uterus and vagina have been
reported in some mammals (Lakomy et al., 1994; Skobowiat et al.,
2009), while mu and delta opioid receptors are present in human
and mouse myometrium (Zhu and Pintar, 1998; Fanning et al.,
2013). Functional measures of peripheral opioid receptor activa-
tion are not well documented for FRT afferents. However in GIT
(Armstrong et al., 2005; Page et al., 2008) and bladder (Su et al.,
1997) mechanosensitive sensory axons are modulated by opioid
receptor agonists.
TRP CHANNELS
The TRP family of channels have been a focus of somatic pain
research for some time. TRPV1 channels are present on presumed
nociceptive axons in rat vagina (Liao and Smith, 2011) and human
cervix (Tingåker et al., 2008). Interestingly these have been pro-
posed to underlie some of the adverse side effects of clotrimazole,
an anti-mycotic agent (Meseguer et al., 2008). Furthermore estro-
gen ampliﬁes pain evoked by uterine distension, via a TRPV1
receptor dependent mechanism (Yan et al., 2007). Information on
other TRP channels (e.g., TRPM8 and TRPA1) is limited in the
FRT although they are expressed on sensory nerves supplying the
GIT (Blackshaw et al., 2010).
TROPHIC FACTORS
Various growth factors particularly nerve growth factor (NGF) and
members of the glial cell line-derived neurotrophic factor family of
ligands are implicatednot only in survival of some sensoryneurons
but their receptors have been suggested as targets for alleviating
neuropathic pain (Koltzenburg et al., 1999; Boucher et al., 2000;
Malin et al., 2006; Malin and Davis, 2008). Within the FRT NGF
has been reported in the uterus (Lobos et al., 2005) and cervix
(Chalar et al., 2003) andneurturinmRNAhas been found inuterus
(Widenfalk et al., 2000). Sensory neurons innervating the uterus
were shown to express tyrosine receptor kinaseA receptors (Chalar
et al., 2003). Whether growth factors or their receptors modulate
sensory afferent neurons from the FRT is unknown although they
are implicated in bladder signaling (Klinger and Vizzard, 2008;
Schnegelsberg et al., 2010).
P2X RECEPTORS
ATP was implicated in pain signaling nearly four decades ago
(Bleehen andKeele,1977). The subsequent discoveryof P2X recep-
tors on sensory nerves (Cook et al., 1997) had led to much work
on identifying subtypes of P2X receptors as therapeutic targets
(North and Jarvis, 2013). Detailed studies of the FRT are lacking
however P2X receptors have been identiﬁed on both uterine and
cervical sensory axons (Papka et al., 2005).
METABOTROPIC GLUTAMATE RECEPTORS (mGluRs)
mGluR have been implicated in uterine and cervix sensory sig-
naling (Ghosh et al., 2007) where they may modulate sensory
discharge during parturition. Within the GIT peripheral mGluR
on sensory endings modulate excitability (Page et al., 2005) where
they have been proposed as therapeutic targets (Blackshaw et al.,
2011).
ACID SENSING ION CHANNELS (ASICs)
No studies to date have tested whether ASIC are expressed on
sensory neurons innervating the FRT. However, they are expressed
in vagal (Page et al., 2007) and colonic (Jones et al., 2005) sensory
neurons where they represent a potential therapeutic target.
NITRIC OXIDE
Nitric oxide generated by neuronal, inducible or endothelial nitric
oxide synthase (NOS) plays many roles in the FRT. It is most
notably released by autonomic vasodilator neurons to dramati-
cally increase blood ﬂow (Morris et al., 2005). However nNOS is
also expressed in a subpopulation of sensory nerves (Papka et al.,
1995). The role of nNOS in sensory signaling in the reproductive
tract is unknown. However a role for pain modulation has been
proposed in somatic pain models (Boettger et al., 2007; Keilhoff
et al., 2013) and therapeutic agents that target nNOS have been
proposed (Mladenova et al., 2012).
CANNABINOIDS
The cannabinoid signaling pathways have long been proposed as
therapeutic targets (Roques et al., 2012). The FRT has some of the
highest levels of endogenous cannabinoids (Schmid et al., 1997)
and cannabinoid receptors are expressed in human and rodent
myometrium (Das et al., 1995; Dennedy et al., 2004)where they act
on smooth muscle. Cannabinoid receptors on sensory axons asso-
ciated with the FRT have not been reported. However activation of
cannabinoid type 1 receptors modulates sensory afferent signaling
from the urinary bladder (Walczak et al., 2009) and jejunum (Yuce
et al., 2010).
CURRENT THERAPIES FOR FRT PAIN
Currently evidence based treatment for FRT pain is limited.
Standard pain therapies such as paracetamol, non-steroidal anti-
inﬂammatory drugs (NSAIDs), opioids, or neuropathic pain
therapies have been used, as the type of pain is not well deﬁned and
directing treatment is difﬁcult. Topical therapies are increasing as
options for treating vulvar and vaginal pain and are recommended
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as ﬁrst line treatment (Nunns et al., 2010). Topical therapy presents
an attractive alternative to systemic therapy as they are generally
well tolerated and are associated with less systemic adverse effects.
However, some topical therapies may cause irritation that can
worsen symptoms (Nunns et al., 2010). Currently, due to a lack of
evidence of effectiveness, all topical therapies used in this condi-
tion would be considered experimental (Andrews, 2011). Topical
treatments have also been associated with a high placebo response
(Nunns et al., 2010).
Vulvodynia and vestibulodynia treatment has been the subject
of several recent reviews, which concluded there was insufﬁcient
evidence of effectiveness and safety for a range of therapies. It was
determined there was evidence of a lack of efﬁcacy for botulinum
toxin injection, topical 5% xylocaine, and topical nifedipine.
There was insufﬁcient evidence to evaluate the effectiveness of
steroid, local anesthetic injections, nerve blocks, intramuscular or
intralesional interferon or topical capsaicin,montelukast, steroids,
gabapentin, and ketoconazole (Andrews, 2011). Oral treatments
that include tricyclic antidepressants, serotonin–norepinephrine
uptake inhibitors and anticonvulsants (Cox and Neville, 2012)
lack good quality evidence of effectiveness and have systemic
adverse effects. Physical and alternative therapies are also used
but there are only anecdotal reports of effectiveness (Andrews,
2011; Cox and Neville, 2012). Surgery has also been used
effectively to treat vulvar vestibular pain (Nunns et al., 2010;
Andrews, 2011; Cox and Neville, 2012). Estrogen therapies are
effective in patients where the pain is linked to low estrogen lev-
els following menopause or breast cancer treatment (Goetsch,
2012). Less common therapeutic options that have shown suc-
cess in small clinical trials include cutaneous ﬁbroblast lysate
cream (Donders and Bellen, 2012), nitroglycerin cream (Walsh
et al., 2002), and amitriptyline-baclofen cream (Nyirjesy et al.,
2009).
Treatment of uterine pain is limited to systemic options with
little evidence. Dysmenorrhea is the best-studied uterine pain syn-
drome. Primary dysmenorrhea is treated with simple analgesics,
usually naproxen, while secondary dysmenorrhea treatment relies
on removal of the underlying cause of the pain (Kohle and
Deb, 2011). As other pelvic organs can cause pelvic pain a thor-
ough investigation is important. Non-pharmacological therapies
including nutrition and lifestyle changes, along with surgery may
play a role. Further investigation is needed to determine the most
appropriate treatments for uterine pain.
Further investigation is needed to determine speciﬁc targets for
pharmacological management of the various FRT pain sub-types.
The use of drug delivery systems may be required to effectively
deliver existing or experimental compounds to the target site for
improved efﬁcacy and/or to reduce systemic adverse effects.
DELIVERING THERAPIES TO THE FRT
The intravaginal route of drug administration has been studied
as a suitable site for local and systemic delivery of therapeutic
agents. The degree to which therapies act locally or systemi-
cally is formulation dependent. Presently intravaginal therapies
are typically prescribed for vaginal infections and vaginal dryness.
Systemic drug delivery includes uterine targeting or treatment of
migraines (Bassi and Kaur, 2012). In relation to pain stemming
from the FRT, the intravaginal route shows promise for the
local or systemic delivery of analgesic and anti-inﬂammatory
agents.
The vagina has unique features that canbe exploited for optimal
therapeutic responses, such as the presence of a dense network of
blood vessels, large surface area, and permeability (Srikrishna and
Cardozo, 2013). In addition, unlike conventional oral therapy,
the vaginal route avoids hepatic ﬁrst-pass metabolism, signiﬁcant
enzymatic degradation of active ingredients and drug interactions
(Bassi and Kaur, 2012). Absorption from vaginal delivery systems
occurs by dissolution, followed by penetration of drug through
the vaginal membrane to reach the systemic circulation (Hussain
and Ahsan, 2005). Physiological factors can affect the drug release
from intravaginal delivery systems and/or vaginal absorption of
drugs, such as cyclic changes in thickness of the vaginal epithelium,
ﬂuid volume and composition, pH and sexual arousal (Hussain
and Ahsan, 2005; das Neves et al., 2011). Although physiological
factors are difﬁcult to alter, the physicochemical properties of a
drug compound (e.g., molecular weight, lipophilicity, ionization,
surface charge, chemical nature; Hussain and Ahsan, 2005) as well
as the formulation can be selected to regulate local versus systemic
activity.
Despite its therapeutic potential, vaginal preparations show low
patient acceptability due to factors including multiple daily dos-
ing; leakage and messiness following application; and the need
for night-time dosing. The effectiveness of commonly available
vaginal dosage forms (creams, gels, solutions, foams, pessaries)
is often limited by their low retention to the vaginal epithelium
(Pavelic´ et al., 2004). In order to overcome these limitations, novel
vaginal delivery systems are being developed that possess desirable
distribution, bioadhesion, and release properties – such as vaginal
rings, bioadhesive delivery systems, and nanosystems.
VAGINAL RINGS
Intravaginal rings (IVRs) are circular drug delivery devices that are
designed to provide both sustained and controlled drug release,
lasting for several weeks to several months following insertion
into the vagina. IVR have been shown to be effective in deliv-
ering a multitude of compounds, such as contraceptive steroids
and steroids for the treatment of post-menopausal atrophy. This
delivery device has been previously reviewed (Baloglu et al., 2009;
Thurman et al., 2013; Srikrishna and Cardozo, 2013).
BIOADHESIVE DRUG DELIVERY (BDD) SYSTEMS
BDD systems were developed to circumvent the issues associated
with conventional vaginal formulations, by adhering to the vaginal
mucosal tissue and prolonging the residence time of the formu-
lation. Vaginal BDD systems have been exploited for both local
as well as systemic delivery of drugs (Merabet et al., 2005; Bassi
and Kaur, 2012). Several studies have focused on BDD systems
in the form of tablets, ﬁlms, patches, and gels for the vaginal
mucosal route that are composed of bioadhesive polymers that are
biocompatible, biodegradable and stable. Common mucoadhe-
sive polymers include tragacanth (acacia), carbopol resins, sodium
alginate, carboxymethylcellulose, and chitosan. Vaginal BDD sys-
tems have been previously reviewed (Baloglu et al., 2009; Bassi and
Kaur, 2012).
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NANOSYSTEMS
Nanocarriers [e.g., dendrimers, liposomes, Poly(lactic-co-glycolic
acid) nanoparticles, silver and gold nanoparticles] have been
utilized in topical drug delivery to enhance the penetration of
drug compounds. For example, encapsulation of drugs within
liposomes can provide characteristics such as enhanced skin or
mucosal permeability, sustained release aswell as controlled release
(Pavelic´ et al., 2004). Such nanosystems are usually incorporated
within a bioadhesive base (e.g., Carbopol resin) to enhance the
viscosity of the formulation for retention on the mucosal surface
(Pavelic´ et al., 2004; dasNeves et al., 2011). The use of nanosystems
is promising for intravaginal drug delivery, however, similar to
BDD systems, the interaction of these formulations with mucosal
ﬂuids present in the vagina at different stages of the menstrual
cycle and age is not yet well deﬁned (Bassi and Kaur, 2012).
CONCLUSION
Pain attributed to the FRT is complex and involves several classes
of nociceptive and non-nociceptive sensory neurons. The unique
neural anatomy of pelvic organs provides challenges in the deliv-
ery of selective therapies. There is little evidence that current
treatments are effective and new strategies need to be developed.
Relative to somatic pain, or pain from the GIT, there is a lack of
information on the basic neurophysiology of FRT sensory neu-
rons. Well deﬁned animal models of neuropathic or inﬂammatory
pain exist for somatic structures (e.g., chronic constriction injury
models) and to some extent colitis (trinitrobenzene sulfonic acid
models). At present there is no consistent approach to FRT pain.
This will need to be addressed if we are to explore the many poten-
tial therapeutic targets present on FRT sensory neurons. Exciting
opportunities exist for development of intravaginal drug deliv-
ery systems for either local or systemic drug delivery. Similar
targeted delivery systems can be developed for the vulvodynias.
Finally larger clinical trials of the few currently available promis-
ing therapies could provide useful insights in directing preclinical
studies.
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